The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...

Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML: Tokyo Thursday, December 12, 2024, 12:00 Hrs [IST] The fir ...

Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by ...

IonQ , a leader in the quantum computing and networking industry, will highlight the transformative power of quantum computing for the future of business at Q2B24 Silicon Valley. At Q2B24, IonQ will ...

Provenir, a global leader in AI-powered risk decisioning software, today announced it has been named the winner in the "Tech of the Future ? AI and Data ? Driving Intelligent Decisions" category for ...

Updates in Hematology Portfolio in Certain Leukemias and Lymphomas At ASH, several sub-analyses of the QuANTUM-First phase 3 trial of VANFLYTA® (quizartinib) in patients with newly diagnosed FLT3 ...

Quizartinib is already approved and on the market in Japan as Vanflyta for adults with relapsed or refractory FLT3-ITD+ AML based on the results of the QuANTUM-R trial, which showed it was ...

Months Before C.E.O.’s Killing, the Suspect Went Silent. Where Was He? New details are emerging about Luigi Mangione’s growing impatience with “a capitalist society” and his search for ...